Table 10.

Viral infections in patients with AML/MDS-HR subjected to treatment with hypomethylating agents: review of the studies published in recent years

References	Therapy	Patients (no.) and Diagnosis	Study type	Rate of viral infections	Type of viral infections
Ali, 2017 (77)	Decitabine	85 pts AML/MDS	Prospective	Incidence of viral infections: 3.7%.	Prevalence of influenza and parainfluenza virus No cases of CMV.
Radsak, 2017 (124)	Azacitidine	918 pts MDS	Review	Review of literature on almost 1000 patients treated with azacitidine. Viral infections not precisely quantified by the authors but reported as rare infectious complications.
Ofran, 2015 (130)	Azacitidine AML/MDS	216 pts	Retrospective	Incidence of viral infections: 4.3%	Prevalently infections of the high respiratory airways and pneumonia.
Sullivan, 2013 (131)	Azacitidine vs 103 pts	103 pts MDS	Control case	Incidence of viral infections, 8%	Almost all of the episodes (7/8) were due to influenza viruses. One case of CMV reactivation.
Khan, 2011 (132)	Azacitidine	1 pt MDS	Case report		The authors report a case of hemorrhagic colitis due to CMV in an MDS patient treated with azacitidine.
Zhou, 2009 (133)	Azacitidine	1 pt MDS	Case report		Case of severe disseminated reactivation of VZV in an MDS patient treated with azacitidine.